Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era
<p>Abstract</p> <p>Purpose</p> <p>This study examined the population-based use and outcomes of brain radiotherapy (BRT) for brain metastases (BM) from breast cancer with a focus on repeat BRT in the trastuzumab era.</p> <p>Methods and materials</p> <...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-12-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.ro-journal.com/content/6/1/181 |
| _version_ | 1828273802314776576 |
|---|---|
| author | Karam Irene Nichol Alan Woods Ryan Tyldesley Scott |
| author_facet | Karam Irene Nichol Alan Woods Ryan Tyldesley Scott |
| author_sort | Karam Irene |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Purpose</p> <p>This study examined the population-based use and outcomes of brain radiotherapy (BRT) for brain metastases (BM) from breast cancer with a focus on repeat BRT in the trastuzumab era.</p> <p>Methods and materials</p> <p>All women with breast cancer diagnosed from 2000-2007 and treated with BRT were retrospectively identified from a provincial database.</p> <p>Results</p> <p>A total of 441 women with BM from breast cancer were identified. The median age was 55 years and 40% (176/441) had human epidermal growth factor receptor 2 (HER2) positive disease. The median survival (MS) from the initial BRT for all 441 women was 4.5 months. The MS by Radiation Therapy Oncology Group Recursive Partitioning Analysis (RPA) class was: 1 (14.5 months), 2 (6.4 months) and 3 (1.8 months). For the 37 cases receiving repeat BRT, 27% (10/37) had stereotactic radiosurgery (SRS) and 70% (26/37) had HER2 positive disease, of which, 81% (21/26) received trastuzumab in the metastatic setting. For repeat BRT, the median survival by RPA class was: 1 (9.8 months), 2 (7.4 months) and 3 (2.0 months). For RPA class 1 and 2, the one-year overall survival (OS) was 45%.</p> <p>Conclusion</p> <p>The proportion of cases with HER2 positive disease was increased at repeat BRT compared to initial BRT. RPA class 1 and 2 patients should be considered for repeat BRT.</p> |
| first_indexed | 2024-04-13T06:25:25Z |
| format | Article |
| id | doaj.art-54c3114069f04160b6253b862e5e06d6 |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-04-13T06:25:25Z |
| publishDate | 2011-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-54c3114069f04160b6253b862e5e06d62022-12-22T02:58:26ZengBMCRadiation Oncology1748-717X2011-12-016118110.1186/1748-717X-6-181Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab eraKaram IreneNichol AlanWoods RyanTyldesley Scott<p>Abstract</p> <p>Purpose</p> <p>This study examined the population-based use and outcomes of brain radiotherapy (BRT) for brain metastases (BM) from breast cancer with a focus on repeat BRT in the trastuzumab era.</p> <p>Methods and materials</p> <p>All women with breast cancer diagnosed from 2000-2007 and treated with BRT were retrospectively identified from a provincial database.</p> <p>Results</p> <p>A total of 441 women with BM from breast cancer were identified. The median age was 55 years and 40% (176/441) had human epidermal growth factor receptor 2 (HER2) positive disease. The median survival (MS) from the initial BRT for all 441 women was 4.5 months. The MS by Radiation Therapy Oncology Group Recursive Partitioning Analysis (RPA) class was: 1 (14.5 months), 2 (6.4 months) and 3 (1.8 months). For the 37 cases receiving repeat BRT, 27% (10/37) had stereotactic radiosurgery (SRS) and 70% (26/37) had HER2 positive disease, of which, 81% (21/26) received trastuzumab in the metastatic setting. For repeat BRT, the median survival by RPA class was: 1 (9.8 months), 2 (7.4 months) and 3 (2.0 months). For RPA class 1 and 2, the one-year overall survival (OS) was 45%.</p> <p>Conclusion</p> <p>The proportion of cases with HER2 positive disease was increased at repeat BRT compared to initial BRT. RPA class 1 and 2 patients should be considered for repeat BRT.</p>http://www.ro-journal.com/content/6/1/181breast cancerbrain metastasisbrain irradiationre-irradiationHER2 positive |
| spellingShingle | Karam Irene Nichol Alan Woods Ryan Tyldesley Scott Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era Radiation Oncology breast cancer brain metastasis brain irradiation re-irradiation HER2 positive |
| title | Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era |
| title_full | Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era |
| title_fullStr | Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era |
| title_full_unstemmed | Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era |
| title_short | Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era |
| title_sort | population based outcomes after whole brain radiotherapy and re irradiation in patients with metastatic breast cancer in the trastuzumab era |
| topic | breast cancer brain metastasis brain irradiation re-irradiation HER2 positive |
| url | http://www.ro-journal.com/content/6/1/181 |
| work_keys_str_mv | AT karamirene populationbasedoutcomesafterwholebrainradiotherapyandreirradiationinpatientswithmetastaticbreastcancerinthetrastuzumabera AT nicholalan populationbasedoutcomesafterwholebrainradiotherapyandreirradiationinpatientswithmetastaticbreastcancerinthetrastuzumabera AT woodsryan populationbasedoutcomesafterwholebrainradiotherapyandreirradiationinpatientswithmetastaticbreastcancerinthetrastuzumabera AT tyldesleyscott populationbasedoutcomesafterwholebrainradiotherapyandreirradiationinpatientswithmetastaticbreastcancerinthetrastuzumabera |